Patents

Home
Achievement
Patents
Patents

Global Technological Ranking of bBHC

  • 1. Ranking by number of patent applications in regenerative medicine technologies: 8th in the world
  • 2. Ranking by number of granted patents in regenerative medicine technologies: 2nd in the world
  • 3. Stem cell technology capability: 6th in the world

Detailed Technology Rankings

  • 1. Adult stem cell field: 2nd in the world
  • 2. Induced pluripotent stem cell field: 4th in the world
  • 3. Stem cell culture (media): 2nd in the world

Source : 2023 Industry Innovation Strategy Based on Patent Big Data (KIPO- Korean Intellectual Property Office)

In 2025, STRI filed
approximately 1,800 additional KH Cells

In 2025, STRI filed approximately 1,800 additional KH Cells (KH Cells: a new type of pluripotent stem cell that does not form tumors but instead eliminates and suppresses cancer cells, while inducing down-aging effects) -related patents—including PCT applications—in 159 countries such as Korea, the United States, EU, Japan, and Australia and etc. As a result, STRI has registered and applied a total of around 2,000 KHC patents.

  • Novel Non-tumorigenic pluripotent Stem Cells (KH Cells)
  • Non-tumorigenic Super-pluripotent Stem Cells (KH Cells) Induced by Algae-derived Extracts and Composition for Inducing the Same
  • Non-tumorigenic Super-pluripotent Stem Cells (KH Cells) Induced by Phlorotannin Compounds and Composition for Inducing the Same
  • Non-tumorigenic Super-pluripotent Stem Cells (KH Cells) Induced by Compounds and Composition for Inducing the Same
  • KH Cell-inducing Composition Treating Mesenchymal Stem Cells and Non-tumorigenic Super-pluripotent Stem Cells (KH Cells) Induced Thereby
  • KH Cell-inducing Composition Treating Umbilical Cord Tissue-derived Mesenchymal Stem Cells and Non-tumorigenic Super-pluripotent Stem Cells (KH Cells) Induced Thereby
  • KH Cell-inducing Composition Treating Bone Marrow-derived Mesenchymal Stem Cells and Non-tumorigenic Super-pluripotent Stem Cells (KH Cells) Induced Thereby
  • KH Cell-inducing Composition Treating Adipose-derived Mesenchymal Stem Cells and Non-tumorigenic Super-pluripotent Stem Cells (KH Cells) Induced Thereby
  • KH Cell-inducing Composition Treating Mesenchymal Stem Cells Differentiated from Induced Pluripotent Stem Cells (iPSCs) and Non-tumorigenic Super-pluripotent Stem Cells (KH Cells) Induced Thereby
  • Composition for Prevention or Treatment of Parkinson’s Syndrome Comprising Non-tumorigenic Super-pluripotent Stem Cells (KH Cells) as an Active Ingredient
  • Composition for Prevention or Treatment of Liver Fibrosis or Cirrhosis Comprising Non-tumorigenic Super-pluripotent Stem Cells (KH Cells) as an Active Ingredient